In 2015, a partnership was established between Cure Network Ventures - a corporation wholly owned by Gladstone Institutes - and the Dolby family. Designated the Cure Network Dolby Acceleration Partners LLC (CNDAP) , the effort was to promote the translational advancement of Gladstone's fundamental discoveries -- bridging the gap between academia and industry. A main focus has been the discovery of small molecules and other therapeutics that could transform the treatment of Alzheimer's disease and related neurological disorders. CNDAP's operating model matches promising scientific programs that are ready for translation with suitable funding sources and serves as a catalyst for the establishment of spin-out companies and partnerships with biotech and pharma companies. In the Summer 2021, CNDAP and Takeda Pharmaceutical Company Limited entered into a research collaboration to develop small molecules targeting tau, a protein involved in Alzheimer's disease and other major brain disorders. Takeda has committed undisclosed financial and in-kind support to this drug development effort, which will leverage critical know-how and innovative technologies developed by Gladstone Institutes
